Coegin Pharma

Coegin Pharma is a biotechnology company focusing on the development of small-molecule drug candidates for the treatment of cancer. The therapeutic platform is based on selective inhibition of the key enzyme cPLA₂α, which plays a central role in inflammation and uncontrolled cell growth. The enzyme is thoroughly validated, both pre-clinically and clinically, and is a relevant therapeutic target in a range of cancers and inflammatory diseases. The company advances development of promising drug candidates to either Phase IIa or Phase IIb and subsequently out-licenses the development projects to major international players.